A Placebo-controlled, Patient and Investigator Blinded, Randomized Parallel Cohort Study to Assess Pharmacodynamics, Pharmacokinetics, Safety, Tolerability and Preliminary Clinical Efficacy of VAY736 and CFZ533 in Patients With Systemic Lupus Erythematosus (SLE)
Latest Information Update: 22 Jun 2026
At a glance
Most Recent Events
- 01 Jun 2026 According to a novartis media release, data from this trial will be presented at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London.
- 17 Sep 2025 Status changed from active, no longer recruiting to completed.
- 28 Jun 2024 The study has been Completed in Germany, According to European Clinical Trials Database record.